JPWO2019222269A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019222269A5 JPWO2019222269A5 JP2020564427A JP2020564427A JPWO2019222269A5 JP WO2019222269 A5 JPWO2019222269 A5 JP WO2019222269A5 JP 2020564427 A JP2020564427 A JP 2020564427A JP 2020564427 A JP2020564427 A JP 2020564427A JP WO2019222269 A5 JPWO2019222269 A5 JP WO2019222269A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- groups
- substituted
- substitution
- alkoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 612
- 238000006467 substitution reaction Methods 0.000 claims description 516
- 229910052739 hydrogen Inorganic materials 0.000 claims description 472
- 239000001257 hydrogen Substances 0.000 claims description 472
- 125000003545 alkoxy group Chemical group 0.000 claims description 305
- 150000001875 compounds Chemical class 0.000 claims description 304
- 125000005843 halogen group Chemical group 0.000 claims description 271
- 125000003342 alkenyl group Chemical group 0.000 claims description 269
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 264
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 190
- 125000002252 acyl group Chemical group 0.000 claims description 183
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 181
- 125000004423 acyloxy group Chemical group 0.000 claims description 179
- 125000003118 aryl group Chemical group 0.000 claims description 152
- 125000001072 heteroaryl group Chemical group 0.000 claims description 107
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 100
- 150000001408 amides Chemical class 0.000 claims description 92
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 90
- 125000003282 alkyl amino group Chemical group 0.000 claims description 89
- -1 hydroxy, carboxy Chemical group 0.000 claims description 86
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 82
- 150000003839 salts Chemical class 0.000 claims description 60
- 125000005415 substituted alkoxy group Chemical group 0.000 claims description 60
- 125000004414 alkyl thio group Chemical group 0.000 claims description 41
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 29
- 208000035475 disorder Diseases 0.000 claims description 15
- 201000010099 disease Diseases 0.000 claims description 14
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 125000003396 thiol group Chemical class [H]S* 0.000 claims description 4
- 239000007822 coupling agent Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 44
- 125000003710 aryl alkyl group Chemical group 0.000 claims 31
- 125000000304 alkynyl group Chemical group 0.000 claims 24
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 23
- 125000004475 heteroaralkyl group Chemical group 0.000 claims 7
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 description 308
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 156
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 120
- 238000000034 method Methods 0.000 description 41
- 101100507655 Canis lupus familiaris HSPA1 gene Proteins 0.000 description 8
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 description 8
- 101001016865 Homo sapiens Heat shock protein HSP 90-alpha Proteins 0.000 description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 239000000203 mixture Substances 0.000 description 6
- 230000033228 biological regulation Effects 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- 239000002841 Lewis acid Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000001361 intraarterial administration Methods 0.000 description 3
- 150000007517 lewis acids Chemical group 0.000 description 3
- 230000004770 neurodegeneration Effects 0.000 description 3
- 208000015122 neurodegenerative disease Diseases 0.000 description 3
- 201000001119 neuropathy Diseases 0.000 description 3
- 230000007823 neuropathy Effects 0.000 description 3
- 208000033808 peripheral neuropathy Diseases 0.000 description 3
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 229910052796 boron Inorganic materials 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 125000005017 substituted alkenyl group Chemical group 0.000 description 2
- 125000003107 substituted aryl group Chemical group 0.000 description 2
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- 101150065749 Churc1 gene Proteins 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 206010012305 Demyelination Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 102100038239 Protein Churchill Human genes 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 229940028435 intralipid Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024098452A JP2024125338A (ja) | 2018-05-14 | 2024-06-19 | 熱ショックタンパク質経路に関連する疾患の治療のための、修飾された糖基を有するビアリールアミド |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862671047P | 2018-05-14 | 2018-05-14 | |
| US62/671,047 | 2018-05-14 | ||
| PCT/US2019/032292 WO2019222269A1 (en) | 2018-05-14 | 2019-05-14 | Biaryl amides with modified sugar groups for treatment of diseases associated with heat shock protein pathway |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024098452A Division JP2024125338A (ja) | 2018-05-14 | 2024-06-19 | 熱ショックタンパク質経路に関連する疾患の治療のための、修飾された糖基を有するビアリールアミド |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021524439A JP2021524439A (ja) | 2021-09-13 |
| JPWO2019222269A5 true JPWO2019222269A5 (https=) | 2022-05-20 |
| JP2021524439A5 JP2021524439A5 (https=) | 2022-05-20 |
| JP7508375B2 JP7508375B2 (ja) | 2024-07-01 |
Family
ID=67002352
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020564427A Active JP7508375B2 (ja) | 2018-05-14 | 2019-05-14 | 熱ショックタンパク質経路に関連する疾患の治療のための、修飾された糖基を有するビアリールアミド |
| JP2024098452A Pending JP2024125338A (ja) | 2018-05-14 | 2024-06-19 | 熱ショックタンパク質経路に関連する疾患の治療のための、修飾された糖基を有するビアリールアミド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024098452A Pending JP2024125338A (ja) | 2018-05-14 | 2024-06-19 | 熱ショックタンパク質経路に関連する疾患の治療のための、修飾された糖基を有するビアリールアミド |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11827664B2 (https=) |
| EP (1) | EP3794009A1 (https=) |
| JP (2) | JP7508375B2 (https=) |
| KR (1) | KR20210021457A (https=) |
| CN (2) | CN119285591A (https=) |
| AU (2) | AU2019271126B2 (https=) |
| BR (1) | BR112020023277A2 (https=) |
| CA (1) | CA3100333A1 (https=) |
| CL (1) | CL2020002957A1 (https=) |
| CO (1) | CO2020015380A2 (https=) |
| EA (1) | EA202092727A1 (https=) |
| IL (2) | IL278698B2 (https=) |
| MX (2) | MX2020012366A (https=) |
| PE (1) | PE20211917A1 (https=) |
| PH (1) | PH12020551941A1 (https=) |
| SG (1) | SG11202011311YA (https=) |
| UA (1) | UA130486C2 (https=) |
| WO (1) | WO2019222269A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT201900660T1 (it) | 2012-02-09 | 2020-01-14 | Univ Kansas | Inibitori c-terminali di hsp90 |
| EP3793565B1 (en) | 2018-05-14 | 2022-01-05 | Gilead Sciences, Inc. | Mcl-1 inhibitors |
| JP7508375B2 (ja) | 2018-05-14 | 2024-07-01 | リアタ ファーマシューティカルズ インコーポレイテッド | 熱ショックタンパク質経路に関連する疾患の治療のための、修飾された糖基を有するビアリールアミド |
| TWI778443B (zh) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1抑制劑 |
| CN114787139B (zh) | 2019-11-26 | 2025-03-11 | 吉利德科学公司 | 用于制备mcl1抑制剂的方法和中间体 |
| EP4247783A1 (en) | 2020-11-19 | 2023-09-27 | Gilead Sciences, Inc. | Processes and intermediates for preparing macrocyclic mcl1 inhibitors |
| WO2023039293A1 (en) * | 2021-09-13 | 2023-03-16 | Rubedo Life Sciences, Inc. | Coumarin derivatives of sugar analogs and uses thereof |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2091171A1 (en) | 1990-09-07 | 1992-03-08 | Adriano Afonso | Antiviral compounds |
| DE19512886A1 (de) | 1995-04-06 | 1996-10-10 | Bayer Ag | Substituierte Cycloalkene |
| FR2792320B1 (fr) | 1999-04-19 | 2003-05-09 | Hoechst Marion Roussel Inc | Nouveaux amides aromatiques substitues par un ribose, leur procede de preparation et leur application comme medicaments |
| AU2002223127A1 (en) | 2000-11-30 | 2002-06-11 | Kissei Pharmaceutical Co., Ltd. Intellectual Property | Glucopyranosyloxybenzyl benzene derivatives, medicinal compositions containing the same and intermediates in the production thereof |
| CA2456281A1 (en) | 2001-09-21 | 2003-04-03 | Novartis Ag | Pyrane derivatives as both ace- and nep- inhibitors |
| US7208630B2 (en) | 2004-10-27 | 2007-04-24 | University Of Kansas | Heat shock protein 90 inhibitors |
| US8212011B2 (en) | 2004-11-03 | 2012-07-03 | University Of Kansas | Novobiocin analogues |
| WO2006050501A2 (en) | 2004-11-03 | 2006-05-11 | University Of Kansas | Novobiocin analogues as anticancer agents |
| US8212012B2 (en) | 2004-11-03 | 2012-07-03 | University Of Kansas | Novobiocin analogues having modified sugar moieties |
| US7622451B2 (en) | 2004-11-03 | 2009-11-24 | University Of Kansas | Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders |
| US9120774B2 (en) | 2004-11-03 | 2015-09-01 | University Of Kansas | Novobiocin analogues having modified sugar moieties |
| CA2620566A1 (en) | 2005-08-30 | 2007-03-08 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
| WO2008061108A2 (en) | 2006-11-15 | 2008-05-22 | Forest Laboratories Holdings Limited | Phthalazine derivatives |
| DE102007002715A1 (de) * | 2007-01-18 | 2008-07-24 | Merck Patent Gmbh | Triazolderivat |
| JP5401329B2 (ja) | 2007-03-20 | 2014-01-29 | キュリス，インコーポレイテッド | Ｈｓｐ９０インヒビターとしての縮合アミノピリジン |
| US7960353B2 (en) | 2007-05-10 | 2011-06-14 | University Of Kansas | Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders |
| ES2475206T3 (es) | 2008-02-01 | 2014-07-10 | Takeda Pharmaceutical Company Limited | Derivados de oxima como inhibidores de HSP90 |
| FR2928645A1 (fr) | 2008-03-14 | 2009-09-18 | Sanofi Aventis Sa | Nouveaux derives de carbazole inhibiteurs d'hsp90, compositions les contenant et utilisation |
| US20100022635A1 (en) | 2008-07-28 | 2010-01-28 | University Of Kansas | Heat shock protein 90 inhibitor dosing methods |
| JP5766617B2 (ja) | 2009-02-20 | 2015-08-19 | ユニバーシティ・オブ・カンザス | 修飾された糖部分を有するノボビオシン類似体 |
| US20110082098A1 (en) | 2009-09-30 | 2011-04-07 | University Of Kansas | Novobiocin analogues and treatment of polycystic kidney disease |
| TW201216957A (en) | 2010-07-13 | 2012-05-01 | Dainippon Sumitomo Pharma Co | Biarylamide derivative or a pharmaceutically acceptable salt thereof |
| ES2647889T3 (es) | 2011-04-05 | 2017-12-27 | Sloan-Kettering Institute For Cancer Research | Inhibidores de la Hsp90 |
| US9056104B2 (en) | 2011-05-20 | 2015-06-16 | The University Of Kansas | Dynamic inhibitors of heat shock protein 90 |
| WO2013112548A1 (en) | 2012-01-23 | 2013-08-01 | University Of South Florida | Gamma-aapeptides with potent and broad-spectrum antimicrobial activity |
| SMT201900660T1 (it) | 2012-02-09 | 2020-01-14 | Univ Kansas | Inibitori c-terminali di hsp90 |
| US9422230B2 (en) | 2013-05-09 | 2016-08-23 | Council Of Scientific And Industrial Research | Process for the preparation of an anticonvulsant agent pregabalin hydrochloride |
| AU2014346483B2 (en) | 2013-11-07 | 2019-01-17 | The University Of Kansas | Biphenylamide derivative Hsp90 inhibitors |
| CA2929243C (en) | 2013-11-11 | 2022-05-03 | The University Of Kansas | Coumarin based hsp90 inhibitors with urea and ether substituents |
| CA2951270C (en) | 2014-06-13 | 2023-07-04 | The University Of Kansas | Triazole modified coumarin and biphenyl amide-based hsp90 inhibitors |
| MX388516B (es) * | 2014-06-24 | 2025-03-20 | Univ Kansas | Bifenil amidas con grupos éter modificados como inhibidores de hsp90 e inductores de hsp70. |
| JP7508375B2 (ja) | 2018-05-14 | 2024-07-01 | リアタ ファーマシューティカルズ インコーポレイテッド | 熱ショックタンパク質経路に関連する疾患の治療のための、修飾された糖基を有するビアリールアミド |
-
2019
- 2019-05-14 JP JP2020564427A patent/JP7508375B2/ja active Active
- 2019-05-14 CA CA3100333A patent/CA3100333A1/en active Pending
- 2019-05-14 EA EA202092727A patent/EA202092727A1/ru unknown
- 2019-05-14 EP EP19732770.3A patent/EP3794009A1/en active Pending
- 2019-05-14 KR KR1020207033977A patent/KR20210021457A/ko active Pending
- 2019-05-14 SG SG11202011311YA patent/SG11202011311YA/en unknown
- 2019-05-14 IL IL278698A patent/IL278698B2/en unknown
- 2019-05-14 PE PE2020001859A patent/PE20211917A1/es unknown
- 2019-05-14 WO PCT/US2019/032292 patent/WO2019222269A1/en not_active Ceased
- 2019-05-14 AU AU2019271126A patent/AU2019271126B2/en active Active
- 2019-05-14 IL IL309891A patent/IL309891B2/en unknown
- 2019-05-14 CN CN202411057163.3A patent/CN119285591A/zh active Pending
- 2019-05-14 MX MX2020012366A patent/MX2020012366A/es unknown
- 2019-05-14 US US17/055,331 patent/US11827664B2/en active Active
- 2019-05-14 MX MX2025007723A patent/MX2025007723A/es unknown
- 2019-05-14 BR BR112020023277-7A patent/BR112020023277A2/pt unknown
- 2019-05-14 UA UAA202007914A patent/UA130486C2/uk unknown
- 2019-05-14 CN CN201980046311.2A patent/CN112513058B/zh active Active
-
2020
- 2020-11-13 PH PH12020551941A patent/PH12020551941A1/en unknown
- 2020-11-13 CL CL2020002957A patent/CL2020002957A1/es unknown
- 2020-12-09 CO CONC2020/0015380A patent/CO2020015380A2/es unknown
-
2023
- 2023-10-12 US US18/485,699 patent/US12595278B2/en active Active
-
2024
- 2024-06-19 JP JP2024098452A patent/JP2024125338A/ja active Pending
- 2024-11-29 AU AU2024267017A patent/AU2024267017A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021524439A5 (https=) | ||
| US7399754B2 (en) | N2-quinoline or isoquinoline substituted purine derivatives | |
| JP2001514664A (ja) | ヒドロキシおよびエーテル含有オキシアルキレンエステル類およびその使用 | |
| JP2017521496A5 (https=) | ||
| KR20150023217A (ko) | 페닐 카바메이트 화합물의 통증의 완화 또는 치료 용도 | |
| JPWO2019222269A5 (https=) | ||
| JP2009526831A5 (https=) | ||
| US7217706B2 (en) | Propanolamine derivatives | |
| JP3839665B2 (ja) | 置換２−ベンジルアミノ−２−フェニル−アセトアミド化合物 | |
| JP2024056684A (ja) | 置換フェニル又はピリジニル部分を有するｓｅｒｄ三環化合物の製造方法 | |
| US12473305B2 (en) | Pyrazole boronic acid compound, pharmaceutical composition containing same, and uses thereof | |
| Kooybaran et al. | Esophageal lichen planus successfully treated with the JAK1/3 inhibitor tofacitinib | |
| WO2002030872A1 (en) | Novel aliphatic compounds, process for their preparation and their usage | |
| JP2003508381A (ja) | 高脂血症の予防または治療用薬剤の製造のためのビススルホンアミドの使用 | |
| MXPA02004355A (es) | Composiciones de profarmacos de acido 6-metoxi-2-naftilacetico para tratar la inflamacion. | |
| JPWO2021142247A5 (https=) | ||
| JP7680955B2 (ja) | ロイコトリエン合成阻害剤 | |
| TH2001006527A (th) | ไบเอริล เอไมด์ที่มีหมู่น้ำตาลที่ถูกดัดแปลงสำหรับการบำบัดโรคที่เกี่ยวข้องกับวิถีของฮีตช็อคโปรตีน | |
| JPWO2022195454A5 (https=) | ||
| US11053202B2 (en) | Compositions for the treatment of hypertension and/or fibrosis | |
| EP3989935A1 (en) | Composition and methods for the treatment of anal and rectal disorders | |
| US12612391B2 (en) | Cromolyn derivatives and uses thereof | |
| CN101190917B (zh) | 3,4-二氢-3-甲基-4-氧代咪唑[5,1-d]并1,2,3,5-四嗪-8-甲酸苯磺酰基呋咱氮氧基酯类化合物,制备方法及其用途 | |
| AU2023309139B2 (en) | Substituted imidazo [1, 2-a] pyridine compounds and the use thereof in the treatment and prevention of fibrosis | |
| US20250002512A1 (en) | Novel anti-depressant and neuroplastic agents and therapeutic uses thereof |